MCID: INF009
MIFTS: 30

Inflammatory Spondylopathy

Categories: Bone diseases

Aliases & Classifications for Inflammatory Spondylopathy

MalaCards integrated aliases for Inflammatory Spondylopathy:

Name: Inflammatory Spondylopathy 12 15
Inflammatory Spondylopathies in Disease Classified Elsewhere 12
Inflammatory Spondylopathy in Disease Classified Elsewhere 12
Inflammatory Spondylopathies in Disease Ec 12
Spondylitis 70

Classifications:



External Ids:

Disease Ontology 12 DOID:12105
ICD9CM 34 720.81
SNOMED-CT 67 6963001
ICD10 32 M46.8 M46.9
UMLS 70 C0021396 C0038012

Summaries for Inflammatory Spondylopathy

MalaCards based summary : Inflammatory Spondylopathy, is also known as inflammatory spondylopathies in disease classified elsewhere, and has symptoms including sciatica An important gene associated with Inflammatory Spondylopathy is LINC00523 (Long Intergenic Non-Protein Coding RNA 523). The drugs Adalimumab and Pamidronate have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and t cells.

Related Diseases for Inflammatory Spondylopathy

Symptoms & Phenotypes for Inflammatory Spondylopathy

UMLS symptoms related to Inflammatory Spondylopathy:


sciatica

Drugs & Therapeutics for Inflammatory Spondylopathy

Drugs for Inflammatory Spondylopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
2
Pamidronate Approved Phase 4 40391-99-9 4674
3
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
4
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
5
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
9
Etanercept Approved, Investigational Phase 4 185243-69-0
10
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
11
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
15 Natriuretic Peptide, Brain Phase 4
16 Anti-Infective Agents Phase 4
17 Mitogens Phase 4
18 Endothelial Growth Factors Phase 4
19 Cholestyramine Resin Phase 4
20 Tripterygium Phase 4
21 Antibodies Phase 4
22 Immunoglobulins Phase 4
23 Antibodies, Monoclonal Phase 4
24 Antimalarials Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Analgesics Phase 4
29 Anti-Inflammatory Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Cyclooxygenase 2 Inhibitors Phase 4
33 Narcotics Phase 4
34 Analgesics, Opioid Phase 4
35 Antipyretics Phase 4
36 Tocolytic Agents Phase 4
37
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
38
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
40
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
41
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
42
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
43
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
44
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
45
Certolizumab pegol Approved Phase 3 428863-50-7
46
Rebamipide Approved, Investigational Phase 3 90098-04-7
47
Misoprostol Approved Phase 3 59122-46-2 5282381
48
tannic acid Approved Phase 3 1401-55-4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Ustekinumab Approved, Investigational Phase 3 815610-63-0

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Unknown status NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
2 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
3 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
4 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
7 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab 300 mg;Secukinumab 150 mg
10 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
11 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
12 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
13 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
14 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
15 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
16 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
17 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
18 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Completed NCT02492217 Phase 4 Adalimumab
19 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
20 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
21 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
22 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
23 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 Secukinumab (AIN457) 150 mg s.c.;Secukinumab (AIN457) 150 mg s.c.;Placebo - Secukinumab (AIN457) 150 mg s.c.
24 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
25 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
26 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
27 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
28 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Completed NCT02758782 Phase 4 Celecoxib
29 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
30 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
31 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
32 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
33 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
34 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
35 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
36 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
37 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
38 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
39 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
40 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
41 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
42 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
43 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Active, not recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
44 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
45 Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness (IMT) in Patients With Active AS Terminated NCT00910273 Phase 4 etanercept
46 A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Terminated NCT00766402 Phase 4 Tramadol /acetaminophen;Diclofenac
47 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Terminated NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
48 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
49 A Randomized Multicentre Clinical Trial Comparing The Metal on Metal Hip System Versus The Metal on Highly Crossed Linked Polyethylene System Terminated NCT01422564 Phase 4
50 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate

Search NIH Clinical Center for Inflammatory Spondylopathy

Genetic Tests for Inflammatory Spondylopathy

Anatomical Context for Inflammatory Spondylopathy

MalaCards organs/tissues related to Inflammatory Spondylopathy:

40
Bone, Spinal Cord, T Cells, Endothelial, Skin, Bone Marrow, Eye

Publications for Inflammatory Spondylopathy

Articles related to Inflammatory Spondylopathy:

(show top 50) (show all 17342)
# Title Authors PMID Year
1
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. 61
33655421 2021
2
Nonpharmacologic Pain Management in Inflammatory Arthritis. 61
33781495 2021
3
Insights into the pathogenesis of psoriatic arthritis from genetic studies. 61
33712923 2021
4
Comparison of disease activity in patients with ankylosing spondylitis under TNFi or NSAID treatment, is there any difference? An observational study. 61
31558361 2021
5
Non-radiographic axial spondyloarthritis in Tunisia: main characteristics and detailed comparison with ankylosing spondylitis. 61
32974836 2021
6
Rheumatoid arthritis coexisting with ankylosing spondylitis: A report of 22 cases with delayed diagnosis. 61
33787586 2021
7
Effects of water therapy on disease activity, functional capacity, spinal mobility and severity of pain in patients with ankylosing spondylitis: a systematic review and meta-analysis. 61
31355676 2021
8
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. 61
33728937 2021
9
SASDAS: a practical tool to measure disease activity in axSpa patients. Comments on "a prospective study of novel disease activity indices for ankylosing spondylitis". 61
33427918 2021
10
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. 61
32926247 2021
11
Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. 61
32845439 2021
12
Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis. 61
33532928 2021
13
Exploring simplified disease activity indices in Ankylosing Spondylitis in different populations is the need of the hour. 61
33591371 2021
14
Ankylosing spondylitis rehabilitation publications and the global productivity: a Web of Science-based bibliometric analysis (2000-2019). 61
33797569 2021
15
IFNA1 and IFNA13 Genes Confer Genetic Predisposition to Ankylosing Spondylitis-Associated Uveitis in a Chinese Population. 61
32990094 2021
16
Associations of toll-like receptor 4 and 2 gene polymorphisms with susceptibility to ankylosing spondylitis: A meta-analysis. 61
33369094 2021
17
Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. 61
33811177 2021
18
Sex differences in brain modular organization in chronic pain. 61
33044396 2021
19
The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. 61
33481054 2021
20
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study. 61
33787605 2021
21
Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. 61
33544244 2021
22
Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. 61
32813981 2021
23
Enthesitis may be one of the signs of severe disease in familial Mediterranean fever. 61
32920724 2021
24
The usefulness and validity of English-language videos on YouTube as an educational resource for spondyloarthritis. 61
32880051 2021
25
Fibromyalgia in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: prevalence and screening. 61
32949312 2021
26
Reviewing disease activity indices in spondyloarthritis from the gender perspective: A systematic review and meta-analysis. 61
33795327 2021
27
The structural, functional and electrophysiological assessment of paraspinal musculature of patients with ankylosing spondylitis and non-radiographic axial spondyloarthropathy. 61
33502552 2021
28
Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis. 61
32476522 2021
29
Biomechanical influence of the surgical approaches, implant length and density in stabilizing ankylosing spondylitis cervical spine fracture. 61
33727613 2021
30
Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis. 61
33676382 2021
31
Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis. 61
33548121 2021
32
The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication - a cross sectional study over 3 months in Germany. 61
33704418 2021
33
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. 61
33595833 2021
34
Changes in bone formation regulator biomarkers in early axial spondyloarthritis. 61
32888036 2021
35
RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre-post intervention study. 61
33762234 2021
36
Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis. 61
33768576 2021
37
Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review. 61
33433730 2021
38
Metabolomic analysis of biochemical changes in the tissue and urine of proteoglycan-induced spondylitis in mice after treatment with moxibustion. 61
32953451 2021
39
Validity, reliability, and factor structure of the Istanbul Low Back Pain Disability Index in axial spondyloarthritis. 61
32075459 2021
40
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. 61
33650469 2021
41
Atorvastatin combined with low-dose dexamethasone for vascular endothelial cell dysfunction induced by chronic subdural hematoma. 61
32985481 2021
42
Treatment of single-segment suppurative spondylitis with the transforaminal endoscopic focal cleaning and drainage. 61
31180827 2021
43
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2021
44
A diagnostic model for differentiating tuberculous spondylitis from pyogenic spondylitis on computed tomography images. 61
33768287 2021
45
Psoriasis-Arthritis und ankylosierende Spondylitis. 61
33710581 2021
46
Culture-negative versus culture-positive in pyogenic spondylitis and analysis of risk factors for relapse. 61
33683182 2021
47
Correction to: Post-transplant manifestation of ankylosing spondylitis: a case report and review of literature. 61
33658011 2021
48
Dysphagia in a patient with ankylosing spondylitis: A case report. 61
33728307 2021
49
Are the earlier disease onset and uveitis affected by the HLA-B*27 subtypes in ankylosing spondylitis? Comments on the article by Silmani et al. 61
33763800 2021
50
Evaluation of an ankylosing spondylitis education and self-management program: Beneficial effects on ankylosing spondylitis specific outcomes. 61
33694321 2021

Variations for Inflammatory Spondylopathy

Expression for Inflammatory Spondylopathy

Search GEO for disease gene expression data for Inflammatory Spondylopathy.

Pathways for Inflammatory Spondylopathy

GO Terms for Inflammatory Spondylopathy

Sources for Inflammatory Spondylopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....